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Chitosan (CS) nanoparticles have been developed as a versatile drug delivery system to transport drugs, genes, proteins, and
peptides into target sites. Demands on ﬂuorescent nanoparticles have increased recently due to various applications in medical
and stem-cell-based researches. In this study, ﬂuorescent CS nanoparticles were prepared by a mild method, namely, complex
coacervation. Entrapment eﬃciency of sulforhodamine (SR101) loaded into CS nanoparticles was investigated to evaluate their
capacityinincorporatingﬂuorescentmolecule.Particlesizeofproducedﬂuorescentnanoparticleswasintherangeof600–700nm,
and their particle size was highly dependent on the CS molecular weight as well as concentration. A high entrapment eﬃciency of
SR101 into CS nanoparticles could also be obtained when it was dissolved in methanol. In conclusion, highly loaded ﬂuorescent
CS nanoparticles could be easily prepared using complex coacervation method and therefore can be applied in various medical
researches.
1.Introduction
In the last decade a strong emphasis has been given to
the research and applications in the area of nanoscience
and nanotechnology to bring advancement in the diagnosis
and treatment of diseases. One of the focuses of nanotech-
nology is formulating therapeutic agents in biocompatible,
polymeric, and submicron sized nanocomposites such as
nanoparticles, nanocapsules, micellar systems, and conju-
gates [1].
Among polymeric nanoparticles available, chitosan
nanoparticles have received a considerable amount of atten-
tion as a potential delivery system for drugs, genes, proteins,
and peptides by diﬀerent routes of administration. Chitosan
(CS) is a polysaccharide that derived from deacetylation of
chitin [2] and is a basic and positively charged hydrophilic
polymer. The presence of amino group makes the CS easier
to interact with various biomolecules such as protein, DNA,
enzyme, and antibody. Besides, CS nanoparticles can also
be used as a suitable matrix for attaching biomolecules and
ﬂuorescent molecules simultaneously [3].
CS nanoparticles can be prepared through several meth-
ods such as ionic gelation, complex coacervation, emulsion
cross-linking,andspraydrying[4,5].Amongthesemethods,
ionic gelation and complex coacervation are mild processes
occurring in a pure aqueous environment [6], and the
two methods are very similar except that ionic gelation
involves the gelation of chitosan using an electrolyte such as
tripolyphosphate (TPP), whereas the complex coacervation
employs an oppositely charged ionic polymer [7]s u c ha s
dextran sulfate (DS) [6].
The use of DS in the preparation of chitosan nanoparti-
cles is gaining popularity as it is a biodegradable, biocompat-
ible,andwater-solublepolyanion.Besides,enhancedstability
even in low pH [8] and increased mechanical strength are
among the advantages of using DS as opposed to TPP
which also highly inﬂuence the use of CS nanoparticles
a sad r u gd e l i v e r ys y s t e m[ 4]. The combination of CS
and DS as matrix materials to incorporate Rhodamine 6G
has been reported, but these nanoparticles were negatively
charged since nanosized particles could only be obtained
when the charge ratio of sulfate (N) from DS and amino2 ISRN Pharmaceutics
and imine groups (P) from Rhodamine 6G was 2.24 or
greater [6]. Nanoparticles with positive value of surface
charge are favorable in transporting any molecules into cells
because, besides high loading capacity, a higher cellular
uptake could be achieved compared with negatively charged
nanoparticles [9] as opposite charges between nanoparticles
and cell membrane would facilitate a better interaction and
subsequently cellular internalization [10].
In this research, attempts have been made to produce
positively charged ﬂuorescent CS nanoparticles in which
sulforhodamine101(SR101),awater-solubleredﬂuorescent
dye, was loaded into the nanoparticles. The need for high-
capacity and easy-to-prepare ﬂuorescent nanoparticles is
paramount due to its various applications in medical and
drug delivery research, for example, investigating neuronal
morphology, monitoring regulated exocytosis and endocy-
tosis [11–15]a sw e l la si ns t e mc e l l st h e r a p y ,a n da c t i n ga sa
labeling agent to allow visualisation of implanted cells [16].
The main objectives of this research therefore were to
prepare and determine the entrapment eﬃciency of SR-
101-loaded into CS nanoparticles, as well as to determine
certain formulation factors that could aﬀect their physical
characteristics which include particle size, size distribution,
and zeta potential.
2.Methodology
2.1. Materials. High-molecular-weight chitosan powder
(HMW, molecular weight >310kDa and degree of deacetyla-
tion >85%), low-molecular-weight chitosan powder (LMW,
molecular weight of 50–190kDa and degree of deacetyla-
tion 75%–85%), acetic acid, and sulforhodamine 101 were
purchased from Sigma-Aldrich (USA). Dextran sulfate was
obtained from Fisher Scientiﬁc (Canada), while methanol
and acetone were obtained from R & M Marketing (Essex,
UK). All solvents used were of analytical grade.
2.2. Methods
2.2.1. Preparation of CS-DS Nanoparticles. CS-DS nanopar-
ticles were prepared by the complex coacervation of CS and
DS. High-molecular-weight (HMW) and Low-molecular-
weight (LMW) CS were used to prepare 0.2, 0.1, and 0.05%
w/vCSsolutionbydissolvingrequiredamountofCSpowder
in 2%v/v acetic acid solution. DS powder was dissolved
in distilled water to prepare 0.2, 0.15, 0.1, and 0.05%w/v
DS solution. After that, each 1mL of DS solutions was
added to each 4mL CS solutions under magnetic stirring by
using WiseStir digital multipoint magnetic stirrer, MS-MP8
(DAIHAN Scientiﬁc, Korea) at 250rpm for 15 minutes. All
samples were made in triplicate.
2.2.2. Preparation of SR-101-Loaded CS-DS Nanoparticles.
SR 101 loading into CS-DS nanoparticles was performed by
incorporation method. A SR101 solution of concentration
0.9mg/mL was ﬁrst prepared by dissolving SR101 either in
methanol or directly in 0.1 or 0.05%w/v DS solution. A
volume of 1mL 0.1 and 0.05%w/v DS solutions containing
SR 101 was then added to the 0.1 and 0.05% CS solution,
respectively, under magnetic stirring as above. For the SR
101 dissolved in methanol, the solution was mixed with DS
solution prior to adding to CS solution. All samples were
made in triplicate.
2.2.3. Nanoparticles Characterisation. Particle size, zeta po-
tential (surface charge), and polydispersity (PDI) were mea-
sured using the Zetasizer Nano ZS (Malvern Instruments,
UK). The particle size measurement was performed using
a quartz cell. The particle size analysis of each sample was
performed at 25◦C with a detection angle of 90◦ with three
repeated measurements. For zeta potential measurements,
samples were measured under 25◦C. All following Z-average
was reported as mean particle sizes. The particle size
distribution was reported as a polydispersity index (PDI).
2.2.4. Entrapment Eﬃciency of SR 101. The amount of SR-
101-loaded in the nanoparticles was calculated by the dif-
ference between the total amount SR 101 added to the
nanoparticles formation medium and the amount of free
SR 101 remaining in the aqueous supernatant. The latter
was determined following the separation of SR 101 loaded
nanoparticles from the aqueous medium by centrifuga-
tion twice (Optima L-100 XP Ultracentrifuge, Beckman-
Coulter, USA, rotor NV 70.1 Ti, Beckman-Coulter, USA)
at 15000rpm and 4◦C for 15 minutes. The SR 101 in
supernatants was measured by UV-Vis spectrophotometer
(double-beam ultraviolet visible spectrophotometer model
UV-1601, Shimadzu, Japan) at the wavelengths of 492 and
536nm for the nanoparticles in which SR 101 dissolved
in methanol and distilled water, respectively. The SR 101
entrapment eﬃciency was calculated from the following
equation:
amount of SR 101 added
amount of SR 101 added
−
amount of free SR 101 in supernatant
amount of SR 101 added
×100.
(1)
2.2.5. Statistical Analysis. Data were summarized as the
means ± standard deviation (SD). Data were analysed with
independent t-test or one-way ANOVA by using SPSS 17.0.
For independent t-test and one-way ANOVA, P values of
<0.05 were considered as statistically signiﬁcant which were
diﬀerent between the groups tested.
3. Results and Discussions
The main aim of this study was to load-water soluble SR
101 into CS nanoparticles via complex coacervation method.
The opposite charges of CS and DS were responsible for the
formation of nanoparticles. DS was used in the study as the
oppositely charged polymer because of its higher anionic
charge densities (DS has 2.3 negative charges per monomer
whereas CS contains 0.85 protonable amino groups per
monomer) which therefore could provide suﬃcient anionicISRN Pharmaceutics 3
Table 1: Mean particle size, PDI, and zeta potential of 0.1% w/v LMW CS nanoparticles at diﬀerent concentrations of DS, n = 3.
Concentration of DS
(%w/v)
Mean particle size (nm)
±SD
Mean (PDI)
±SD
Mean particle zeta
potential (mV)
±SD
0.2 864.1 ±437.98 0.7 ±0.13 +36.8 ±0.29
0.15 396.1 ±17.00 0.4 ±0.04 +49.3 ±1.39
0.1 364.0 ±15.21 0.4 ±0.02 +56.6 ±4.09
0.05 316.4 ±54.86 0.4 ±0.07 +62.4 ±0.42
Table 2: Mean particle size, PDI, and zeta potential of 0.05 and 0.1% w/v HMW CS nanoparticles at diﬀerent concentrations of DS, n = 3.
0.05% w/v CS 0.1% w/v CS
[DS]
(%w/v)
Mean particle
size (nm)
±SD
Mean PDI
±SD
Mean zeta
potential (mV)
±SD
Mean particle
size (nm)
±SD
Mean PDI
±SD
Mean zeta
potential (mV)
±SD
0.15 373.1 ±23.33 0.3 ± 0.05 −32.5 ±1.23 1082.1 ±245.67 0.90 ±0.08 +72.5 ±4.27
0.1 1141.3 ±987.10 0.4 ±0.13 +36.4 ±2.39 1532.7 ±284.65 0.98 ±0.01 +84.8 ±6.69
0.05 603.4 ±27.90 0.8 ±0.12 +78.1 ±1.46 1439.7 ±129.74 1.00 ±0+ 8 9 .2 ±2.98
charge to cross-link CS by electrostatic force [17]. Further-
more,theformationofnanoparticleswasstronglyinﬂuenced
by the molecular weight and concentration of CS and DS.
3.1. Eﬀect of DS and CS Concentrations on Unloaded CS
Nanoparticles. Table 1 represents the data on the eﬀects of
diﬀerent concentrations of DS on physical characteristics of
nanoparticles made from 0.1%w/v LMW CS. DS concen-
tration of 0.2%w/v produced nanoparticles with the largest
particle size and least homogenous. It was also observed
that this formulation produced the least stable nanoparticle
system as phase separation occurred after a while. In contrast
to that, nanoparticles with the size less than 400nm were
obtained when 0.15, 0.1, and 0.05%w/v DS were mixed with
0.1%w/v LMW CS. On the other hand, zeta potential of CS
nanoparticles increased with the reduction of DS concentra-
tions (one-way ANOVA, Tukey’s post hoc analysis, P<0.05,
Table 1). This, therefore, suggested that CS nanoparticles
were more stable when DS concentration is in the range
of 0.15–0.05%w/v. Improvement in physical stability of CS
nanoparticles with the decrease in concentration of DS was
thought to be due to their high positive zeta potential which
makes these particles tend to repel with each other and there
will be no tendency for them to aggregate.
Diﬀerent from LMW CS, particle size of most formula-
tions that were produced from HMW CS was beyond nano-
size range. Particle size of all formulations was more than
1µm when 0.1%w/v of CS was used (Table 2). It was also
observed that double layers were formed when 0.05%w/v
DS was used which suggests that this nanoparticulate system
wasphysicallyunstable.Similarresultswerealsoobtainedfor
0.2%w/v CS solution which produced large nanoparticles,
between 4 and 7 microns (data was not shown). The same
trendseenpreviouslywiththeLMWCSforthezetapotential
of these nanoparticles when DS concentration was reduced
(one-way ANOVA, Tukey’s post hoc, P<0.05).
Furthermore, a smaller particle size could only be
obtained when 0.05%w/v CS was used, and the smallest
particle size was obtained when DS concentration was
0.15%w/v. Although it produced the smallest particle size,
thenanoparticleswerenegativelycharged.Thenegativevalue
of this nanoparticulate system was thought to be due to the
high concentration of DS compared to others as DS carries
negative charges. DS concentrations less than 0.15%w/v
produced nanoparticles with positive surface charge.
3.2. Incorporation of SR 101 into CS-DS Nanoparticles. In
this experiment, two formulations were used: (1) 0.1%w/v
of DS with 0.1%w/v LMW CS and (2) 0.05%w/v DS
with 0.05%HMW CS. They were chosen based on the
formulations that produced particle size in the desired size
range for both CS molecular weights and with the positive
zeta potential. The value of zeta potential preferably is less
t h a n6 0m V .Av e r yh i g hz e t ap o t e n t i a lv a l u ew a sa v o i d e dt o
reduce risk of cytotoxicity. SR-101-loaded CS nanoparticles
were obtained spontaneously upon the mixing of the DS
solution with the CS solution under magnetic stirring. The
incorporation of SR 101 into the HMW CS nanoparticles
resulted in a decrease in particle size when compared
to the empty CS nanoparticles (Table 3). In contrast to
that, increased particle size was observed when SR101
was incorporated into the LMW CS nanoparticles. Despite
increment in size, particle size of LMW CS was smaller than
the HMW CS nanoparticles. This was thought to be due to
the decreased viscosity of the LMW chitosan which resulted
in more eﬃcient interaction between negatively charged DS
and cationic Cs. However, incorporation of SR101 into these
nanoparticles could not be achieved as their entrapment
eﬃciency was less than 10% for both formulations. This was
expected to be due to the instability of SR 101 in water
which, therefore, could not be eﬃciently loaded into the
nanoparticles.4 ISRN Pharmaceutics
Table 3: Eﬀect of solvent used to dissolve SR101 on mean particle size, PDI, and zeta potential of SR-101-loaded CS nanoparticles, n = 3.
Distilled water Methanol
Mean particle
size (nm)
±SD
Mean (PDI)
±SD
Mean zeta
potential (mV)
±SD
Mean particle
size (nm)
±SD
Mean (PDI)
±SD
Mean zeta
potential (mV)
±SD
0.1% DS & LMW
CS 394.07 ±23.29 0.38 ±0.02 +54.30 ±1.18 620.03±185.16 0.51 ±0.14 +33.68 ±16.46
0.05% DS & HMW
CS 499.17 ±21.22 0.67 ±0.12 +69.50 ±1.70 687.53±222.36 0.59 ±0.18 +44.78 ±16.31
Even though SR 101 is soluble in water, it is not stable
in water (measured pH of about 6) as its stability decreases
in acidic condition and most stable at pH 8.5 [18]. The
above nanoparticles, therefore, were reformulated by ﬁrst
dissolving SR 101 either in methanol or acetone. It was
observed that SR 101 was fully dissolved in methanol and
formed deeply coloured solution but partially dissolved in
acetone. As SR 101 was fully dissolved in methanol and the
measured pH of methanol was 8.6, SR 101 was, therefore,
dissolved in methanol prior to preparing nanoparticles. The
solution was then mixed with DS solution before adding the
mixture into CS solution under magnetic stirring in which
the loaded nanoparticles were spontaneously formed.
As shown in Table 3, the incorporation of SR 101 in
methanol into the CS-DS nanoparticles resulted in increase
in particle size of the nanoparticles compared with the
empty nanoparticles. This indicated that SR 101 was success-
fully incorporated into the CS nanoparticles. Besides, zeta
potential for both formulations was lower than the previous
formulations when the SR 101 was directly dissolved in
DS solution. On the other hand, the results obtained for
entrapment eﬃciency also suggested that by dissolving SR
101 in the basic methanol, increased amount of SR 101 could
be loaded into nanoparticles. The entrapment eﬃciency of
the two formulations was approximately 96%, indicating
that almost all SR 101 added was incorporated into the CS
nanoparticles.Ionicinteractionbetweenthesulfategroupsof
DSandaminoaswellasiminegroupsofSR101wasexpected
to be the determinant for the SR 101 entrapment eﬃciency
[6].
4. Conclusions
This study demonstrated that positively charged ﬂuorescent
CS nanoparticles could be obtained by a mild method like
complex coacervation, and a high entrapment eﬃciency of
ﬂuorescent molecules in CS nanoparticles could be achieved
by dissolving SR 101 in a basic medium, for example,
methanol. Additionally, a smaller particle size of ﬂuorescent
CS nanoparticles could be obtained by using LMW CS and
adjusting CS concentration. It is also suggested that CS-
DS nanoparticle is a versatile nanoparticulate system which
could be used in various medical applications.
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